2020
Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines
Lacouture ME, Sibaud V, Anadkat MJ, Kaffenberger B, Leventhal J, Guindon K, Abou‐Alfa G. Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines. The Oncologist 2020, 26: e316-e326. PMID: 33021006, PMCID: PMC7873330, DOI: 10.1002/onco.13552.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBile Duct NeoplasmsBile Ducts, IntrahepaticHumansMorpholinesPyrimidinesPyrrolesQuality of LifeReceptors, Fibroblast Growth FactorConceptsSelective FGFR inhibitorsAdverse eventsDermatologic adverse eventsTyrosine kinaseFibroblast growth factor receptor tyrosine kinaseFGFR inhibitorsBladder cancerGrowth factor receptor tyrosine kinaseSkin eventsReceptor tyrosine kinasesPalmar-plantar erythrodysesthesia syndromeSelective fibroblast growth factor receptor (FGFR) inhibitorFibroblast growth factor receptor inhibitorManagement guidelinesGrowth factor receptor inhibitorsSkin adverse eventsTypical adverse eventsFrequent adverse eventsPossible adverse eventsEffective treatment strategiesBiological functionsEffective management plansQuality of lifeDermatologic eventsFGFR fusions
2019
The life-threatening eruptions of immune checkpoint inhibitor therapy
Coleman EL, Olamiju B, Leventhal JS. The life-threatening eruptions of immune checkpoint inhibitor therapy. Clinics In Dermatology 2019, 38: 94-104. PMID: 32197753, DOI: 10.1016/j.clindermatol.2019.10.015.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsAcute generalized exanthematous pustulosisSevere cutaneous adverse reactionsImmune checkpoint inhibitorsStevens-Johnson syndromeToxic epidermal necrolysisManagement of irAEsImmune checkpoint inhibitor therapyCell death ligand 1Generalized exanthematous pustulosisCheckpoint inhibitor therapyCutaneous adverse reactionsDeath ligand 1Life-threatening presentationCell death 1Cytotoxic T lymphocytesLife-threatening eruptionsDermatologic toxicitiesExanthematous pustulosisICPI therapyNeutrophilic dermatosisCheckpoint inhibitorsEpidermal necrolysisAdverse eventsCutaneous eruptionLobular neutrophilic panniculitis associated with DNA methyltransferase inhibitors in the treatment of myeloid disease
Coleman E, Panse G, Cowper S, Prebet T, Gore S, Leventhal J. Lobular neutrophilic panniculitis associated with DNA methyltransferase inhibitors in the treatment of myeloid disease. Journal Of Cutaneous Pathology 2019, 46: 930-934. PMID: 31254406, DOI: 10.1111/cup.13537.Peer-Reviewed Original ResearchConceptsLobular neutrophilic panniculitisNeutrophilic panniculitisDNA methyltransferase inhibitorNeutrophilic eccrine hidradenitisInjection site reactionsAcute myelogenous leukemiaMethyltransferase inhibitorNeutrophilic dermatosisSweet's syndromeMaculopapular eruptionCutaneous toxicityHistopathologic characteristicsSite reactionsNext-generation agentsDifferential diagnosisMyelogenous leukemiaTreatment considerationsMyeloid diseasesPanniculitisTreatmentInhibitorsFirst reportGangrenosumHidradenitisEcchymosis
2018
Erythema Nodosum–like Eruption in the Setting of Sorafenib Therapy
Coleman EL, Cowper SE, Stein SM, Leventhal JS. Erythema Nodosum–like Eruption in the Setting of Sorafenib Therapy. JAMA Dermatology 2018, 154: 369-370. PMID: 29453869, DOI: 10.1001/jamadermatol.2017.5733.Peer-Reviewed Case Reports and Technical Notes
2017
Generalized lichen nitidus-like eruption in the setting of mogamulizumab and tremelimumab
Li AW, Ko CJ, Leventhal JS. Generalized lichen nitidus-like eruption in the setting of mogamulizumab and tremelimumab. European Journal Of Dermatology 2017, 27: 325-326. PMID: 28414193, DOI: 10.1684/ejd.2017.2989.Peer-Reviewed Original Research